SciBX: Science-Business eXchange Contents: October 9 2014, Volume 7 / Issue 39

If you are unable to see the message below, click here to view.

TABLE OF CONTENTS October 9 2014, Volume 7 / Issue 39 Analysis Cover Story Targets and Mechanisms The Distillery: Therapeutics Autoimmune disease Cancer Hematology Infectious disease Musculoskeletal disease Neurology Various The Distillery: Techniques Assays and screens Disease models Drug platforms Advertisement Biopharma Dealmakers A supplement to Nature Biotechnology and Nature Reviews Drug Discovery The September 2014 issue of Biopharma Dealmakers showcases companies with partnering opportunities. This week, find out about how you can collaborate with Chiome Bioscience   Cover Story Top Invigorating IVIG Stephen Parmley doi:10.1038/scibx.2014.1138 arGEN-X is adding to a wave of innovation in IVIG therapy with an engineered recombinant IgG that cleared unwanted antibodies in nonhuman primates 30 times more efficiently than standard IVIG. Full Text | PDF Targets and Mechanisms Top MIDAS touch vaccine Benjamin Boettner doi:10.1038/scibx.2014.1139 A vaccine against the fibrinogen-binding MIDAS domain in the ebpA protein of Enterococcus faecalis could provide a solution to the widespread problem of catheter-associated urinary tract infections. Full Text | PDF BetaLogics' in vitro β cells Kai-Jye Lou doi:10.1038/scibx.2014.1140 BetaLogics and University of British Columbia researchers have developed an in vitro protocol to generate mature insulin-producing β-like cells from human pluripotent stem cells—a major milestone in the development of cell-based therapies to treat diabetes. Full Text | PDF Ral-lying around Ras Chris Cain doi:10.1038/scibx.2014.1141 A University of Colorado–led team has demonstrated anticancer efficacy for new small molecule inhibitors of Ral proteins—a family of Ras-like GTPases often overlooked in favor of their Ras cousins. Full Text | PDF Distillery: Therapeutics Autoimmune disease Top Type I interferon receptor doi:10.1038/scibx.2014.1142 Mouse studies suggest a type I interferon (IFN) receptor superagonist fused to an N-terminal proline-alanine-serine polypeptide chain could be useful for treating MS. Full Text | PDF UDP-Gal:βGlcNAc β-1,4-galactosyltransferase polypeptide 6 (B4GALT6); lactosylceramide doi:10.1038/scibx.2014.1143 Studies in patient samples and mice suggest inhibiting B4GALT6 could help treat MS. Full Text | PDF Cancer Top MicroRNA-33a (miR-33a); phosphodiesterase-8A (PDE-8A); UV radiation resistance associated (UVRAG) doi:10.1038/scibx.2014.1144 Studies in patient samples and mice suggest antagonizing miR-33a could help treat brain cancer. Full Text | PDF F-box protein 11 (FBXO11); snail1 (SNAI1) doi:10.1038/scibx.2014.1145 Mouse and cell culture studies suggest promoting FBXO11-mediated degradation of SNAI1 could help prevent cancer and metastasis. Full Text | PDF Prostate apoptosis response-4 protein (PAR-4; PAWR) doi:10.1038/scibx.2014.1146 In vitro and mouse studies suggest the PAR-4 secretagogue arylquin 1 could help treat cancer. Full Text | PDF Tn antigen; toll-like receptor 9 (TLR9) doi:10.1038/scibx.2014.1147 Mouse studies suggest a cancer vaccine incorporating tumor-associated carbohydrate mimetics could help treat cancer. Full Text | PDF Tumor necrosis factor α–induced protein 8-like 3 (TNFAIP8L3; TIPE3); phosphoinositide 3-kinase (PI3K) doi:10.1038/scibx.2014.1148 Studies in human samples and mice suggest inhibiting TNFAIP8L3 could help treat cancers that depend on oncogenic PI3K activity. Full Text | PDF v-Ral simian leukemia viral oncogene homolog A (RalA); RalB doi:10.1038/scibx.2014.1149 In vitro and mouse studies have identified small molecule inhibitors of the Ral family of GTPases that could help treat cancer. Full Text | PDF IL-10 doi:10.1038/scibx.2014.1150 Mouse studies suggest orally available microparticles that deliver IL-10 could help suppress polyposis to prevent colorectal cancer. Full Text | PDF Histone deacetylase (HDAC) doi:10.1038/scibx.2014.1151 In vitro and mouse studies suggest thioacetate-lactam carboxamide analog–based pan-HDAC inhibitors could help treat colorectal or ovarian cancer. Full Text | PDF MicroRNA-34a (miR-34a) doi:10.1038/scibx.2014.1152 Mouse and cell culture studies identified a new small molecule that could help treat hepatocellular carcinoma (HCC) by activating miR-34a, a known tumor suppressor in the indication. Full Text | PDF p38 Mitogen-activated protein kinase (p38 MAPK; MAPK14) doi:10.1038/scibx.2014.1153 Mouse studies suggest inhibiting MAPK14 could help treat liver cancers that have developed resistance to the receptor tyrosine kinase (RTK) inhibitor Nexavar sorafenib. Full Text | PDF Vitamin D receptor (VDR) doi:10.1038/scibx.2014.1154 In vitro and mouse studies suggest vitamin D analogs could help treat pancreatic cancer. Full Text | PDF Transmembrane protease serine 2 (TMPRSS2) doi:10.1038/scibx.2014.1155 In vitro and mouse studies suggest inhibiting TMPRSS2 could help prevent prostate cancer metastasis. Full Text | PDF Hematology Top Heat shock protein 70 (Hsp70); GATA binding protein 1 (GATA1) doi:10.1038/scibx.2014.1156 Patient sample and in vitro studies suggest inhibiting the interaction between Hsp70 and α-globin hemoglobin chains could help treat β-thalassemia. Full Text | PDF Infectious disease Top Anti-thrombin III (AT3; SERPINC1) doi:10.1038/scibx.2014.1157 In vitro and mouse studies suggest an AT3 fragment could help treat bacterial infections. Full Text | PDF Pentraxin 3 long (PTX3) doi:10.1038/scibx.2014.1158 Mouse studies suggest the N-terminal domain of PTX3 could help treat sepsis. Full Text | PDF Musculoskeletal disease Top Docking protein 7 (DOK7) doi:10.1038/scibx.2014.1159 Mouse model studies suggest DOK7 gene therapy could help treat neuromuscular diseases characterized by small neuromuscular junctions (NMJs), such as limb-girdle myasthenia and muscular dystrophy. Full Text | PDF Neurology Top Serotonin (5-HT4) receptor; acetylcholinesterase (AChE); amyloid precursor protein (APP) doi:10.1038/scibx.2014.1160 In vitro and mouse studies identified a dual serotonin (5-HT4) receptor partial agonist and AChE inhibitor that could help treat AD. Full Text | PDF Nicotinamide phosphoribosyltransferase (NamPRT; NAMPT) doi:10.1038/scibx.2014.1161 In vitro and mouse studies have identified a series of aminopropyl carbazole–based NAMPT inhibitors that could help treat traumatic brain injury. Full Text | PDF Various Top BET bromodomain proteins; bromodomain containing 4 (BRD4); NF-κB doi:10.1038/scibx.2014.1162 Mouse and cell culture studies suggest inhibitors against BET bromodomain proteins such as BRD4 could block NF-κB-mediated super-enhancer formation to help treat inflammation and atherosclerosis. Full Text | PDF Distillery: Techniques Assays and screens Top Single-molecular-interaction sequencing (SMI-seq) technology for multiplexed protein interaction profiling doi:10.1038/scibx.2014.1163 A method for multiplexed profiling of protein interactions could be useful in drug screening applications. Full Text | PDF Disease models Top Conditional ATG6 autophagy related 6 homolog (Becn1; Atg6) knockout mouse model of preterm labor doi:10.1038/scibx.2014.1164 Mouse studies suggest mice with conditional Becn1 knockout could be useful as models to study preterm labor and evaluate therapeutic candidates. Full Text | PDF Mouse model of pain-associated anxiety and depression doi:10.1038/scibx.2014.1165 A mouse model of neuropathic pain could help identify therapeutics to treat pain-associated anxiety and depression. Full Text | PDF Drug platforms Top Generation of insulin-producing cells from human embryonic stem cells (hESCs) to treat type 1 diabetes doi:10.1038/scibx.2014.1166 A protocol to generate insulin-producing cells from hESCs could be useful for developing cellular therapies to treat type 1 diabetes. Full Text | PDF Top Advertisement Biopharma Dealmakers A supplement to Nature Biotechnology and Nature Reviews Drug Discovery The September 2014 issue of Biopharma Dealmakers showcases companies with partnering opportunities. This week, find out about how you can collaborate with arGEN-X

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant) For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our customer feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2014 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.